Eli Lilly vs Pfizer (LLY vs PFE)
Eli Lilly (LLY) vs Pfizer (PFE) in plain English: P/E, growth, margins, debt and dividend side by side, key differences and which fits each investor profile.
Eli Lilly (LLY) and Pfizer (PFE) compete in healthcare and pharma. Here are Eli Lilly and Pfizer side by side with their real figures as of November 4, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Eli Lilly or Pfizer.
Eli Lilly vs Pfizer: the figures
| Figure | Eli Lilly | Pfizer |
|---|---|---|
| Share price | $1,417.99 (November 4, 2026) | $30.79 (November 4, 2026) |
| Market cap | $1.26 trillion | $175.5 billion |
| P/E (TTM) | 46.0x | 44.0x |
| Forward P/E | 28.3x | 10.6x |
| Revenue growth (quarter) | +38.6% | -0.4% |
| Net margin (TTM) | 31.9% | 6.3% |
| Net debt / EBITDA | 1.0x | N/A |
| Dividend yield | 0.49% | 5.73% |
| Beta | 0.39 | N/A |
Eli Lilly and Pfizer figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026; N/A means that Eli Lilly or Pfizer figure is not available, and we never estimate it.
3 key differences between Eli Lilly and Pfizer
- Growth: Eli Lilly grew sales +38.6% year on year in its latest quarter, against -0.4% for Pfizer.
- Profitability: for every 100 of sales, Eli Lilly keeps 31.9 as net profit and Pfizer keeps 6.3.
- Dividend: Pfizer yields 5.73% at today's price and Eli Lilly yields 0.49%.
Eli Lilly or Pfizer: which fits your profile
- If you want growth: Eli Lilly is growing faster today, so it fits better with investors who put business growth first, usually accepting a higher P/E and a bumpier ride.
- If you want income (dividends): Pfizer pays the higher dividend relative to its price.
- If price is what matters most to you: Pfizer trades on the lower P/E; check first whether that is an opportunity or a sign of a business that grows less.
Neither Eli Lilly nor Pfizer wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.
How Eli Lilly and Pfizer make money
Eli Lilly (LLY)
Eli Lilly sells prescription medicines. Its largest revenue source is tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, followed by Verzenio for breast cancer, Jardiance and Trulicity for diabetes, Taltz for immunology and Kisunla for Alzheimer's disease. The United States is its biggest market. Full Eli Lilly analysis.
Pfizer (PFE)
Pfizer sells medicines and vaccines grouped into Primary Care, which includes the blood thinner Eliquis shared with Bristol Myers, Prevnar and Comirnaty vaccines and the antiviral Paxlovid; Specialty Care, led by Vyndaqel; and Oncology, with Ibrance, Xtandi and Seagen drugs like Padcev. The U.S. is its biggest market. Full Pfizer analysis.
Frequently asked questions: Eli Lilly vs Pfizer
Is Eli Lilly or Pfizer the better stock?
Choosing between Eli Lilly and Pfizer depends on what you are looking for. Eli Lilly is growing faster right now, and Pfizer trades on the lower P/E. Fintols does not tell you whether to buy Eli Lilly or Pfizer: it shows you the differences so you can decide.
Which pays a higher dividend, Eli Lilly or Pfizer?
As of November 4, 2026, Pfizer yields 5.73% and Eli Lilly yields 0.49%. Also check how much of their profit Eli Lilly and Pfizer pay out: if it is more than they earn, it cannot last.
Which is more expensive, Eli Lilly or Pfizer?
On P/E, Eli Lilly (46.0x) is more expensive than Pfizer (44.0x) as of November 4, 2026. A higher P/E can be justified if earnings grow faster, so compare it with each company's growth in the table.
Can I own both Eli Lilly and Pfizer?
Yes. Many people spread their money across several companies, such as Eli Lilly and Pfizer, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Eli Lilly or Pfizer.
More comparisons with Eli Lilly or Pfizer
More companies like Eli Lilly and Pfizer: healthcare and pharma stocks. Educational content about Eli Lilly and Pfizer, not investment advice.